At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antidepressants; Anxiolytics; Indoles; Pyridines
- Mechanism of Action Enzyme inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 25 Aug 1998 No-Development-Reported for Depression (Unknown route)
- 09 Jan 1997 Preclinical development for Depression (Unknown route)